← Back to Home

Iberdomide Triplet Therapy Delays Myeloma Progression: Median Progression-Free Survival Reaches 42 Months in Phase 3 Trial

A confirmatory analysis of 800 patients showed that the iberdomide combination reduced the risk of disease progression or death by 51% compared with the control group, adding evidence of clinical benefit to the accelerated approval previously supported by minimal residual disease measures; overall survival and full safety results have yet to be disclosed.

By SURL BioNews

For patients with relapsed or refractory multiple myeloma, whether a treatment can keep the disease from progressing for longer is an important consideration when switching therapies. On October 8, Bristol Myers Squibb announced new results from the phase 3 EXCALIBER-RRMM trial: iberdomide combined with daratumumab and dexamethasone achieved a median progression-free survival of 42 months, more than twice the 20 months achieved with the control regimen.

This confirmatory analysis included 800 patients, randomly assigned to two groups of 400 each. All participants were adults whose disease had progressed after one to two prior lines of treatment. Both groups received daratumumab and dexamethasone; the difference was that the new regimen added iberdomide, while the control regimen added bortezomib. This was a multicenter, open-label trial, with treatment continuing until disease progression or unacceptable toxicity.

According to the company announcement and reporting by CancerNetwork, at a median follow-up of 23 months, the hazard ratio for disease progression or death with the new regimen versus the control group was 0.49, equivalent to a 51% reduction in relative risk, with a statistical P value of less than 0.000001. The trial thus met the other of its two co-primary endpoints: progression-free survival.

This result addresses how long the disease can remain without progression and cannot yet be directly interpreted as showing that patients live longer. The 42 months is also an estimated median based on the current follow-up data and does not mean that every patient has been observed for that long. The announcement has not yet provided the confidence interval for the hazard ratio, detailed subgroup results, or overall survival data. The precision of the benefit estimate and its applicability still await clarification through the full analysis.

The new data also add a different level of evidence to the earlier efficacy signal. Targeted Oncology reported that an earlier analysis involving 420 patients, at a median follow-up of 15.7 months, found a minimal residual disease (MRD)-negative complete response rate of 41.1%, compared with 20.7% in the control group. This means that after patients achieved a complete response, highly sensitive testing still detected no residual cancer cells. OncLive noted that this measure had supported the U.S. Food and Drug Administration's accelerated approval of the combination in August 2026. The progression-free survival results now provide further support that deeper treatment responses can translate into more durable disease control.

Beyond efficacy, the treatment burden in both groups also needs to be weighed. The company said the safety findings in this analysis were consistent with previous results, but it has not yet released the full adverse event details from the 800-patient analysis. Early results compiled by Targeted Oncology showed higher rates of severe neutropenia and infections in the iberdomide group, but less peripheral sensory neuropathy. Thus, “consistent with previous results” does not mean that side effects were mild.

The full progression-free survival data are expected to be presented at the American Society of Hematology annual meeting, to be held December 12–15 in New Orleans. Whether longer-term disease control comes with an acceptable treatment burden, and whether different patient populations benefit equally, will be important considerations in determining the clinical role of this triplet regimen.

References

  1. Bristol Myers Squibb
  2. CancerNetwork
  3. OncLive
  4. Targeted Oncology